NCT01491594 - Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Sarcoma, Soft TissueOsteosarcomaNeoplasms, Connective and Soft Tissue

Interventions

DRUG

Eltrombopag

Eltrombopag is taken by mouth daily beginning 5 days before the start of each chemotherapy cycle for 10 days. In the phase 1 part of the study the dose will be 100, 150, 225, or 300 mg.

Trial Locations (1)

27710

Duke Cancer Center, Durham